GOCM Gynecology and Obstetrics Clinical Medicine

Gynecology and Obstetrics Clinical Medicine is committed to open peer review. As part of this commitment, we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

Gynecology and Obstetrics Clinical Medicine is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (**gocm.bmj.com**).

If you have any questions on *Gynecology and Obstetrics Clinical Medicine*'s open peer review process please email info.gocm@bmj.com

GOCM Gynecology and Obstet Clinical Medicine

MINIMALLY INVASIVE METHODS TO TREAT UTERINE FIBROIDS: UTILITY OR ADVERTISING?

Journal:	*Gynecology and Obstetrics Clinical Medicine*
Manuscript ID	gocm-2024-000020
Article Type:	Editorial
Date Submitted by the Author:	05-Mar-2024
Complete List of Authors:	Tinelli, Andrea; Veris Delli Ponti Scorrano Hospital
Keywords:	Gynecologic Surgical Procedures, Gynecology, Women's Health, Uterine Neoplasms, Uterine Diseases

SCHOLARONE™
Manuscripts

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

MINIMALLY INVASIVE METHODS TO TREAT UTERINE FIBROIDS: UTILITY OR ADVERTISING?

Andrea Tinelli, MD, Prof, PhD
Department of Obstetrics and Gynecology and CERICSAL (CEntro di RIcerca Clinico SALentino), Veris delli Ponti Hospital, Scorrano, Lecce, Italy.
Orcid ID: 0000-0001-8426-8490
Email: andreatinelli@gmail.com

The most prevalent benign uterine tumors, known as fibroids or myomas, is a type of monoclonal tumor that develops from the growth of smooth muscle cells, with a significant amount of extracellular matrix, affecting about 70% of middle-aged women. While many fibroids are asymptomatic, 25–50% of them can result in pelvic pain and pressure, abnormal uterine bleeding, intestinal and/or urine symptoms, and/or issues with infertility [1].

Progestins/estroprogestins and gonadotropin-releasing hormone (GnRH) agonists are two commonly used medicinal treatments for uterine fibroids. By acting as a suppressant on both estrogens and progesterone, these methods can regulate heavy monthly bleeding and alleviate symptoms in patients [2]. The danger of uncommon but severe liver damage has led to a recent decline in the prescription of ulipristal acetate (UPA), a selective progesterone receptor modulator, despite its well-established efficacy in treating fibroids [3]. Because of their pharmacodynamic qualities, oral GnRH antagonists are becoming more and more popular in the treatment of fibroid disorders because they can lower circulating sex hormone levels in a dose-dependent manner. To clarify their potential use in the treatment of fibroids in the future, fresh information on their cost, safety, and effectiveness is necessary [4]. Research has partially elucidated the mechanisms of action for alternative potential molecules, such as vitamin D and epigallocatechin gallate (EGCG), among natural medicines for fibroids [5].

Women with fibroids should have customized treatment, which is typically determined by the patient's age and desire for future pregnancy, the size, quantity, and location of the fibroid, the clinical symptoms, and the availability of various therapeutic alternatives.

Surgical therapy options include myomectomy for patients with unsatisfied reproductive desires and hysterectomy as a last procedure for women who do not wish to preserve future fertility [6].

The literature has recently proposed some minimally invasive methods for the therapy of fibroids, which aim to present themselves as an alternative to traditional surgical therapy and subsequently to pharmacological therapy.

To mitigate some of the hazards associated with traditional surgery, minimally invasive procedures utilizing heat-producing devices, such as radiofrequency (RF), have been developed. The focused tissue undergoes irreversible degeneration, coagulation, and necrosis as a result of the RF treatment,

which uses an alternating current operating at a frequency of 300–500 kHz. This energy is then transformed into heat. It also requires the least amount of time to recuperate, leaves no scar behind, and appears to cause no myometrial damage [7].

Under the guidance of ultrasound or magnetic resonance, the high-intensity focused ultrasound (HIFU) concentrates low-intensity ultrasound in vitro on the target area in vivo. This creates a high-energy density focus, which causes the surrounding tissue to heat up quickly. The thermal effect of the ultrasound is then used to cause local coagulation necrosis of solid tumors, or ablation. Clinical trials validated the safety and effectiveness of HIFU for fibroids health technology, which was approved by the US Food and Drug Administration in 2004 [8].

One type of vascular interventional therapy is uterine artery embolization (UAE). The UAE stops the flow of blood to the uterus by using non-spherical polyvinyl alcohol or tris-acryl gelatin microspheres, which results in ischemic necrosis of the fibroids. The main goal of the UAE treatment for fibroids is to stop the growth of the lesions by generating ischemia necrosis. After that, the lesions can dissolve, absorb, shrink, or even go away, which would relieve the patient's discomfort. The problem is that this procedure treats the whole uterus, rather than the fibroids specifically, and has the potential of permanent impairment uterine and ovarian function [9].

The impact of performing all of these minimally invasive methods to treat fibroids on future fertility and on possible gynecologic malignancy of these “fibroids” is still unknown.

The myometrium's biology, which is highly complex given that it is a dynamic reproductive viscera that can weigh anywhere from 50 grams to 1.5 kg at term of pregnancy, is the major issue regarding the potential impact of these procedures on conception. The thin structure of the myometrium facing the fibroid, the pseudocapsule, dividing it from the myometrium, must now be discussed. The fibroid pseudocapsule, a neurofibrovascular network that completely envelops the fibroid and supplies it with blood and hormones [10]. Through its own circulatory network, the pseudocapsule itself supplies vascular supplementation. Furthermore, the nerve fibers of the pseudocapsule are rich in neurotransmitters for myometrial biological function and for the post-myomectomy physiological myometrial healing, as a neurofibrovascular bundle [11].

There has never been an assessment of how any of these techniques (RF, HIFU, UAE) affects the pseudocapsule. Since the pseudocapsule measuring only 1-3 mm, the injury to this thin and delicate neurofibrovascular structure is a plausible hypothesis. During a myomectomy, in fact, the myometrium must never be touched because damaging the muscle will render it useless. The fibroid pseudocapsule is an integral component of the muscle and should never be damaged or in a necrotic state. If not, the muscle in that region will fibrose and become useless for the myometrium's physiology [11,12]. Furthermore, the transient hypoxia produced by UAE impacts muscle and

endometrial biology. What type of impact this is, whether negative or not, we do not know and nor can we know as we haven't yet published in vivo studies on the biological effects of transient hypoxia on the myometrium and endometrium.

Finally, one crucial factor to take into account when treating fibroids is the potential for an underlying, concealed cancer to be discovered. Because the symptoms of benign fibroid illness and cancer, particularly leiomyosarcoma (LMS), are similar, it can be challenging to differentiate between the two on a clinical basis. Currently, there is no conclusive laboratory or imaging test that can accurately distinguish between these entities. When myomectomy or hysterectomy is performed for symptomatic assumed benign fibroid illness, the frequency and prognosis of concealed LMS are unknown. Between 1 in 350 and 1 in 8,000 cases are included in these incidence estimates [13].

A group of authors studied 491 patients following HIFU or UAE to determine the finding of future detection of malignancy in women who have nonsurgical therapy for uterine fibroid disease using HIFU and UAE techniques. A total of 106 people had their fibroids surgically treated after that. Four individuals (1.2%) out of the 346 patients who had follow-up had a diagnosis of leiomyosarcoma following their interventional treatment for fibroids. Two more cases of endometrial adenocarcinoma and one case of an endometrial premalignant lesion were reported [14].

What we have illustrated and discussed must make us reflect on the indiscriminate diffusion of these alternative methods to surgery and drug therapy, thinking critically either about their actual usefulness and effectiveness, or about the cost-effectiveness and the possible side effects of the procedures.

Funding: This research received no external funding.

Conflicts of Interest: There are no competing interests for the author.

Clinical trial registration: the article is an editorial and hasn't any Clinical Trial Registration.

Ethics Approval Statement: the article is an editorial and hasn't any Ethics Approval Statement

References

1. Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epidemiology of Uterine Myomas: A Review. Int J Fertil Steril. 2016 Jan-Mar;9(4):424-35.
2. Ali M, Ciebiera M, Wlodarczyk M, Alkhrait S, Maajid E, Yang Q, Hsia SM, Al-Hendy A. Current and Emerging Treatment Options for Uterine Fibroids. Drugs. 2023 Dec;83(18):1649-1675.
3. Tinelli A, Kosmas IP, Mynbaev OA, Malvasi A, Sparic R, Vergara D. The Biological Impact of Ulipristal Acetate on Cellular Networks Regulating Uterine Leiomyoma Growth. Curr Pharm Des. 2020;26(3):310-317.
4. de Lange ME, Semmler A, Clark TJ, Mol BWJ, Bet PM, Huirne JAF, Hehenkamp WJK. Considerations on implementation of the newest treatment for symptomatic uterine fibroids: Oral GnRH antagonists. Br J Clin Pharmacol. 2024 Feb;90(2):392-405.

5. Tinelli A, Panese G, Licchelli M, Morciano A, Pecorella G, Gambioli R. The impact of epigallocatechin gallate, vitamin D, and D-chiro-inositol on early surgical outcomes of laparoscopic myomectomy: a pilot study. Arch Gynecol Obstet. 2024 Mar;309(3):1021-1026.
6. Tinelli A, Kosmas IP, Catherino WH, Carugno J, Mynbaev OA, Sparic R, Trojano G, Malvasi A. Laparoscopic Intracapsular Myomectomy in Women 40 Years Old and Over with Symptomatic Uterine Fibroids. A Pilot Study. Surg J (N Y). 2021 Mar 22;7(1):e47-e53.
7. Fasciani A, Turtulici G, Siri G, Ferrero S, Sirito R. A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas. Medicina (Kaunas). 2020 Mar 12;56(3):122.
8. Patel N, Chaudhari K, Patel D, Joshi J. High-Intensity Focused Ultrasound Ablation of Uterine Fibroids: A Review. Cureus. 2023 Sep 4;15(9):e44680.
9. Wu Q, Motaghi M, Tang H, Hazhirkarzar B, Shaghaghi M, Ghadimi M, Baghdadi A, Rezvani R, Mohseni A, Borhani A, Madani SP, Afyouni S, Zandieh G, Kamel IR. Outcome prediction for symptomatic patients with fibroids who underwent uterine artery embolization. Clin Imaging. 2024 Jan;105:110028.
10. Tinelli A, Favilli A, Lasmar RB, Mazzon I, Gerli S, Xue X, Malvasi A. The importance of pseudocapsule preservation during hysteroscopic myomectomy. Eur J Obstet Gynecol Reprod Biol. 2019 Dec;243:179-184.
11. Mettler L, Tinelli A, Hurst BS, Teigland CM, Sammur W, Dell'edera D, Negro R, Gustapane S, Malvasi A. Neurovascular bundle in fibroid pseudocapsule and its neuroendocrinologic implications. Expert Rev Endocrinol Metab. 2011 Sep;6(5):715-722.
12. Tinelli A, Malvasi A, Hurst BS, Tsin DA, Davila F, Dominguez G, Dell'edera D, Cavallotti C, Negro R, Gustapane S, Teigland CM, Mettler L. Surgical management of neurovascular bundle in uterine fibroid pseudocapsule. JSLS. 2012 Jan-Mar;16(1):119-29.
13. Sparić R, Andjić M, Babović I, Nejković L, Mitrović M, Štulić J, Pupovac M, Tinelli A. Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review. Int J Mol Sci. 2022 Aug 27;23(17):9728.
14. Leonardo-Pinto JP, Maghsoudlou P, Salazar GM, Clark NV, Koch RM, Ajao MO, Einarsson JI, Rassier SLC. Diagnosis of gynecologic malignancy after the treatment of presumed benign fibroid disease with interventional radiology procedures: a retrospective cohort study. Fertil Steril. 2023 Jul;120(1):125-133.

GOCM Gynecology and Obstet Clinical Medicine

MINIMALLY INVASIVE METHODS WITH NO FIBROID SURGICAL REMOVAL TO TREAT UTERINE FIBROIDS: UTILITY OR ADVERTISING?

Journal:	*Gynecology and Obstetrics Clinical Medicine*
Manuscript ID	gocm-2024-000020.R1
Article Type:	Editorial
Date Submitted by the Author:	27-Apr-2024
Complete List of Authors:	Tinelli, Andrea; Veris Delli Ponti Scorrano Hospital
Keywords:	Gynecologic Surgical Procedures, Gynecology, Women's Health, Uterine Neoplasms, Uterine Diseases

SCHOLARONE™
Manuscripts

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

MINIMALLY INVASIVE METHODS WITH NO FIBROID SURGICAL REMOVAL TO TREAT UTERINE FIBROIDS: UTILITY OR ADVERTISING?

Andrea Tinelli, MD, Prof, PhD
Department of Obstetrics and Gynecology and CERICSAL (CEntro di RIcerca Clinico SALentino), Veris delli Ponti Hospital, Scorrano, Lecce, Italy.
Orcid ID: 0000-0001-8426-8490
Email: andreatinelli@gmail.com

The most prevalent benign uterine tumors, known as fibroids or myomas, is a type of monoclonal tumor that develops from the growth of smooth muscle cells, with a significant amount of extracellular matrix, affecting about 70% of middle-aged women. While many fibroids are asymptomatic, 25–50% of them can result in pelvic pain and pressure, abnormal uterine bleeding, intestinal and/or urine symptoms, and/or issues with infertility [1].

Women with fibroids should have customized treatment, which is typically determined by the patient's age and desire for future pregnancy, the size, quantity, and location of the fibroid, the clinical symptoms, and the availability of various therapeutic alternatives.

Traditional minimally invasive surgical treatment options include myomectomy for patients with unsatisfied reproductive desires, until to hysterectomy as a last procedure for women who do not wish to preserve future fertility [2].

The literature proposed some alternative minimally invasive non removal surgical methods for fibroid therapy, which aim to present themselves as an alternative to traditional surgical therapy with fibroid removal from uterus.

To mitigate some of the hazards associated with traditional surgery, minimally invasive procedures utilizing heat-producing devices, such as radiofrequency (RF), have been developed. The focused tissue undergoes irreversible degeneration, coagulation, and necrosis as a result of the RF treatment, which uses an alternating current operating at a frequency of 300–500 kHz. This energy is then transformed into heat. It also requires the least amount of time to recuperate, leaves no scar behind [3]. The RF is a technique that works blindly, on an intrauterine mass that could theoretically be neoplastic (given what has happened with the FDA since 2014 in the USA with the morcellation problem). Furthermore, the anatomical-functional changes that occur to the treated mass that is left in place in the myometrium are unknown. Because of the unknowns surrounding the biology of the myometrium, no reproductive society actually advises RF therapy of fibroids for procreative purposes. Lastly, it is unknown how heat from RF would affect the pseudocapsule, the basic biological framework enclosing the fibroid.

Under the guidance of ultrasound or magnetic resonance, the high-intensity focused ultrasound (HIFU) concentrates low-intensity ultrasound in vitro on the target area in vivo. This creates a high-energy density focus, which causes the surrounding tissue to heat up quickly. The thermal effect of the ultrasound is then used to cause local coagulation necrosis of solid tumors, or ablation. Clinical trials validated the safety and effectiveness of HIFU for fibroids health technology, which was approved by the US Food and Drug Administration in 2004 [4].

The same criticisms expressed for RF are equally expressed for HIFU, given that the thermal damage to the fibroid and uterus, produced by this technique, is similar.

One type of vascular interventional therapy is uterine artery embolization (UAE). The UAE stops the flow of blood to the uterus by using non-spherical polyvinyl alcohol or tris-acryl gelatin microspheres, which results in ischemic necrosis of the fibroids. The main goal of the UAE treatment for fibroids is to stop the growth of the lesions by generating ischemia necrosis. After that, the lesions can dissolve, absorb, shrink, or even go away, which would relieve the patient's discomfort. The problem is that this procedure treats the whole uterus, rather than the fibroids specifically, and has the potential of permanent impairment uterine and ovarian function [5].

The UAEs are also questionable in the minimally invasive treatment of fibroids, for the same issues expressed for RF and HIFU. Any intrauterine formation or mass that is treated without enucleation can potentially be an invasive neoplasm. The biological alteration brought about by UAE then establishes a biological influence on the myometrium's functionality that cannot be fully measured, which is why it is not recommended for younger patients who wish to become pregnant.

It is yet uncertain how the uterus will react biologically to all of these minimally invasive non-removal surgical procedures for treating fibroids in terms of future fertility and potential gynecologic cancer of these "supposed fibroids."

The myometrium's biology, which is highly complex given that it is a dynamic reproductive viscera that can weigh anywhere from 50 grams to 1.5 kg at term of pregnancy, is the major issue regarding the potential impact of these procedures on conception. The thin structure of the myometrium facing the fibroid, the pseudocapsule, dividing it from the myometrium, must now be discussed. The fibroid pseudocapsule, a neurofibrovascular network that completely envelops the fibroid and supplies it with blood and hormones [6]. Through its own circulatory network, the pseudocapsule itself supplies vascular supplementation of fibroids. Furthermore, the nerve fibers of the pseudocapsule are rich in neurotransmitters for myometrial biological function and for the post-myomectomy physiological myometrial healing, as a neurofibrovascular bundle [7].

There has never been an assessment of how any of these techniques (RF, HIFU, UAE) affects the pseudocapsule. Since the pseudocapsule measuring only 1-3 mm, the injury to this thin and delicate neurofibrovascular structure is a plausible hypothesis. During a myomectomy, in fact, the myometrium must never be touched because damaging the muscle will render it useless. The fibroid pseudocapsule is an integral component of the muscle and should never be damaged or in a necrotic state. If not, the muscle in that region will fibrose and become useless for the myometrium's physiology [8,9]. Furthermore, the transient hypoxia produced by UAE impacts muscle and endometrial biology. What type of impact this is, whether negative or not, we do not know and nor can we know as we haven’t yet published in vivo studies on the biological effects of transient hypoxia on the myometrium and endometrium.

Finally, one crucial factor to take into account when treating fibroids is the potential for an underlying, concealed cancer to be discovered. Because the symptoms of benign fibroid illness and cancer, particularly leiomyosarcoma (LMS), are similar, it can be challenging to differentiate between the two on a clinical basis. Currently, there is no conclusive laboratory or imaging test that can accurately distinguish between these entities. When myomectomy or hysterectomy is performed for symptomatic assumed benign fibroid illness, the frequency and prognosis of concealed LMS are unknown. Between 1 in 350 and 1 in 8,000 cases are included in these incidence estimates [10].

A group of authors studied 491 patients following HIFU or UAE to determine the finding of future detection of malignancy in women who have nonsurgical therapy for uterine fibroid disease using HIFU and UAE techniques. A total of 106 people had their fibroids surgically treated after that. Four individuals (1.2%) out of the 346 patients who had follow-up had a diagnosis of leiomyosarcoma following their interventional treatment for fibroids. Two more cases of endometrial adenocarcinoma and one case of an endometrial premalignant lesion were reported [11].

What we have illustrated and discussed must make us reflect on the indiscriminate diffusion of these alternative non removal surgical methods, thinking critically either about their actual usefulness and effectiveness, or about the cost-effectiveness and the possible side effects of the procedures, to respond in a scientifically adequate manner to patients with doubts about what to choose to surgically treat a fibroid.

Funding: This research received no external funding.

Contributorship Statement: The author confirms sole responsibility for the following: study conception and design, data collection, analysis and interpretation of results, and manuscript preparation.

Competing Interest Statement: There are no competing interests for the author.

Ethics Approval Statement: No Ethics Approval needed.

References

1. Sparic R, Mirkovic L, Malvasi A, et al. Epidemiology of Uterine Myomas: A Review. Int J Fertil Steril. 2016 Jan-Mar;9(4):424-35.
2. Tinelli A, Kosmas IP, Catherino WH, et al. Laparoscopic intracapsular myomectomy in women 40 years old and over with symptomatic uterine fibroids. A Pilot Study. Surg J (N Y).
3. 2021 Mar 22;7(1):e47-e53.
4. Fasciani A, Turtulici G, Siri G, et al. A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas. Medicina (Kaunas). 2020 Mar 12;56(3):122.
5. Patel N, Chaudhari K, Patel D, et al. High-Intensity Focused Ultrasound Ablation of Uterine Fibroids: A Review. Cureus. 2023 Sep 4;15(9):e44680.
6. Wu Q, Motaghi M, Tang H, et al. Outcome prediction for symptomatic patients with fibroids who underwent uterine artery embolization. Clin Imaging. 2024 Jan;105:110028.
7. Tinelli A, Favilli A, Lasmar RB, et al. The importance of pseudocapsule preservation during hysteroscopic myomectomy. Eur J Obstet Gynecol Reprod Biol. 2019 Dec;243:179-184.
8. Mettler L, Tinelli A, Hurst BS, et al. Neurovascular bundle in fibroid pseudocapsule and its neuroendocrinologic implications. Expert Rev Endocrinol Metab. 2011 Sep;6(5):715-722.
9. Tinelli A, Malvasi A, Hurst BS, et al. Surgical management of neurovascular bundle in uterine fibroid pseudocapsule. JSLS. 2012 Jan-Mar;16(1):119-29.
10. Sparić R, Andjić M, Babović I, et al. Molecular insights in uterine leiomyosarcoma: a systematic review. Int J Mol Sci. 2022 Aug 27;23(17):9728.
11. Leonardo-Pinto JP, Maghsoudlou P, Salazar GM, et al. Diagnosis of gynecologic malignancy after the treatment of presumed benign fibroid disease with interventional radiology procedures: a retrospective cohort study. Fertil Steril. 2023 Jul;120(1):125-133.

GOCM Gynecology and Obstet Clinical Medicine

MINIMALLY INVASIVE METHODS WITH NO FIBROID SURGICAL REMOVAL TO TREAT UTERINE FIBROIDS: UTILITY OR ADVERTISING?

Journal:	*Gynecology and Obstetrics Clinical Medicine*
Manuscript ID	gocm-2024-000020.R2
Article Type:	Editorial
Date Submitted by the Author:	11-Jun-2024
Complete List of Authors:	Tinelli, Andrea; Veris Delli Ponti Scorrano Hospital
Keywords:	Gynecologic Surgical Procedures, Gynecology, Women's Health, Uterine Neoplasms, Uterine Diseases

SCHOLARONE™
Manuscripts

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

MINIMALLY INVASIVE METHODS WITH NO FIBROID SURGICAL REMOVAL TO TREAT UTERINE FIBROIDS: UTILITY OR ADVERTISING?

Andrea Tinelli, MD, Prof, PhD
Department of Obstetrics and Gynecology and CERICSAL (CEntro di RIcerca Clinico SALentino), Veris delli Ponti Hospital, Scorrano, Lecce, Italy.
Orcid ID: 0000-0001-8426-8490
Email: andreatinelli@gmail.com

The most prevalent benign uterine tumors, known as fibroids or myomas, is a type of monoclonal tumor that develops from the growth of smooth muscle cells, with a significant amount of extracellular matrix, affecting about 70% of middle-aged women. While many fibroids are asymptomatic, 25%~50% of them can result in pelvic pain and pressure, abnormal uterine bleeding, intestinal and/or urine symptoms, and/or issues with infertility [1]. Women with fibroids should have customized treatment, which is typically determined by the patient's age and desire for future pregnancy, the size, quantity, and location of the fibroid, the clinical symptoms, and the availability of various therapeutic alternatives.

Traditional minimally invasive surgical treatment options include myomectomy for patients with unsatisfied reproductive desires, until to hysterectomy as a last procedure for women who do not wish to preserve future fertility [2]. Some literatures have proposed some alternative minimally invasive non-removal surgical methods for fibroid therapy, which aim to present themselves as an alternative to traditional surgical therapy with fibroid removal from the uterus.

To mitigate some of the hazards associated with traditional surgery, minimally invasive procedures utilizing heat-producing devices, such as radiofrequency (RF), have been developed. The focused tissue undergoes irreversible degeneration, coagulation, and necrosis as a result of the RF treatment, which uses an alternating current operating at a frequency of 300–500 kHz. This energy is then transformed into heat. It also requires the least amount of time to recuperate, and leaves no scar behind [3]. The RF is a technique that works blindly, on an intrauterine mass that could theoretically be neoplastic (given what has happened with the Food and Drug Administration (FDA) since 2014 in the USA with the morcellation problem). Furthermore, the anatomical-functional changes that occur to the treated mass that is left in place in the myometrium are unknown. Because of the unknowns surrounding the biology of the myometrium, no reproductive society actually advises RF therapy of fibroids for procreative purposes. Lastly, it is unknown how heat from RF would affect the pseudocapsule, the basic biological framework enclosing the fibroid.

Under the guidance of ultrasound or magnetic resonance, high-intensity focused ultrasound (HIFU) concentrates low-intensity ultrasound in vitro on the target area in vivo. This creates a high-energy density focus, which causes the surrounding tissue to heat up quickly. The thermal effect of the ultrasound is then used to cause local coagulation necrosis of solid tumors or ablation. Clinical trials validated the safety and effectiveness of HIFU for fibroids health technology, which was approved by the US FDA in 2004 [4]. The same criticisms expressed for RF are equally expressed for HIFU, given that the thermal damage to the fibroid and uterus, produced by this technique, is similar.

One type of vascular interventional therapy is uterine artery embolization (UAE). The UAE stops the flow of blood to the uterus by using non-spherical polyvinyl alcohol or tris-acryl gelatin microspheres, which results in ischemic necrosis of the fibroids. The main goal of the UAE treatment for fibroids is to stop the growth of the lesions by generating ischemia necrosis. After

that, the lesions can dissolve, absorb, shrink, or even go away, which would relieve the patient's discomfort. The problem is that this procedure treats the whole uterus, rather than the fibroids specifically, and has the potential of permanent impairment of uterine and ovarian function [5]. The UAEs are also questionable in the minimally invasive treatment of fibroids, for the same issues expressed for RF and HIFU. Any intrauterine formation or mass that is treated without enucleation can potentially be an invasive neoplasm. The biological alteration brought about by UAE then establishes a biological influence on the myometrium's functionality that cannot be fully measured, which is why it is not recommended for younger patients who wish to become pregnant.

It is yet uncertain how the uterus will react biologically to all of these minimally invasive non-removal surgical procedures for treating fibroids in terms of future fertility and potential gynecologic cancer of these "supposed fibroids." The myometrium's biology, which is highly complex given that it is a dynamic reproductive viscera that can weigh anywhere from 50 grams to 1.5 kg at term of pregnancy, is the major issue regarding the potential impact of these procedures on conception. The thin structure of the myometrium facing the fibroid, the pseudocapsule, dividing it from the myometrium, must now be discussed. The fibroid pseudocapsule, is a neurofibrovascular network that completely envelops the fibroid and supplies it with blood and hormones [6]. Through its own circulatory network, the pseudocapsule itself supplies vascular supplementation of fibroids. Furthermore, the nerve fibers of the pseudocapsule are rich in neurotransmitters for myometrial biological function and post-myomectomy physiological myometrial healing, as a neurofibrovascular bundle [7].

There has never been an assessment of how any of these techniques (RF, HIFU, UAE) affect the pseudocapsule. Since the pseudocapsule measures only 1-3 mm, the injury to this thin and delicate neurofibrovascular structure is a plausible hypothesis. During a myomectomy, in fact, the myometrium must never be touched because damaging the muscle will render it useless. The fibroid pseudocapsule is an integral component of the muscle and should never be damaged or in a necrotic state. If not, the muscle in that region will fibrose and become useless for the myometrium's physiology [8]. Furthermore, the transient hypoxia produced by UAE impacts muscle and endometrial biology. What type of impact this is, whether negative or not, we do not know, and nor can we know as we haven’t yet published in vivo studies on the biological effects of transient hypoxia on the myometrium and endometrium.

Finally, one crucial factor to take into account when treating fibroids is the potential for an underlying, concealed cancer to be discovered. Because the symptoms of benign fibroid illness and cancer, particularly leiomyosarcoma (LMS), are similar, it can be challenging to differentiate between the two on a clinical basis. Currently, there is no conclusive laboratory or imaging test that can accurately distinguish between these entities. When myomectomy or hysterectomy is performed for symptomatic assumed benign fibroid illness, the frequency, and prognosis of concealed LMS are unknown. Between 1 in 350 and 1 in 8,000 cases are included in these incidence estimates [9]. A group of authors studied 491 patients following HIFU or UAE to determine the finding of future detection of malignancy in women who have nonsurgical therapy for uterine fibroid disease using HIFU and UAE techniques. A total of 106 people had their fibroids surgically treated after that. Four individuals (1.2%) out of the 346 patients who had follow-up had a diagnosis of leiomyosarcoma following their interventional treatment for fibroids. Two more cases of endometrial adenocarcinoma and one case of an endometrial premalignant lesion were reported [10].

What we have illustrated and discussed must make us reflect on the indiscriminate diffusion of these alternative non-removal surgical methods, thinking critically either about their actual

usefulness and effectiveness, or about the cost-effectiveness and the possible side effects of the procedures, to respond in a scientifically adequate manner to patients with doubts about what to choose to surgically treat a fibroid.

Funding: This research received no external funding.

Contributorship Statement: The author confirms sole responsibility for the following: study conception and design, data collection, analysis and interpretation of results, and manuscript preparation.

Competing Interest Statement: There are no competing interests for the author. AT has served as an editorial member of GOCM.

Ethics Approval Statement: No Ethics Approval needed.

References

1. Sparic R, Mirkovic L, Malvasi A, et al. Epidemiology of Uterine Myomas: A Review. Int J Fertil Steril. 2016 Jan-Mar;9(4):424-35.
2. Tinelli A, Kosmas IP, Catherino WH, et al. Laparoscopic intracapsular myomectomy in women 40 years old and over with symptomatic uterine fibroids. A Pilot Study. Surg J (N Y). 2021 Mar 22;7(1):e47-e53
3. Fasciani A, Turtulici G, Siri G, et al. A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas. Medicina (Kaunas). 2020 Mar 12;56(3):122.
4. Patel N, Chaudhari K, Patel D, et al. High-Intensity Focused Ultrasound Ablation of Uterine Fibroids: A Review. Cureus. 2023 Sep 4;15(9):e44680.
5. Wu Q, Motaghi M, Tang H, et al. Outcome prediction for symptomatic patients with fibroids who underwent uterine artery embolization. Clin Imaging. 2024 Jan;105:110028.
6. Tinelli A, Favilli A, Lasmar RB, et al. The importance of pseudocapsule preservation during hysteroscopic myomectomy. Eur J Obstet Gynecol Reprod Biol. 2019 Dec;243:179-184.
7. Mettler L, Tinelli A, Hurst BS, et al. Neurovascular bundle in fibroid pseudocapsule and its neuroendocrinologic implications. Expert Rev Endocrinol Metab. 2011 Sep;6(5):715-722.
8. Tinelli A, Malvasi A, Hurst BS, et al. Surgical management of neurovascular bundle in uterine fibroid pseudocapsule. JSLS. 2012 Jan-Mar;16(1):119-29.
9. Sparić R, Andjić M, Babović I, et al. Molecular insights in uterine leiomyosarcoma: a systematic review. Int J Mol Sci. 2022 Aug 27;23(17):9728.
10. Leonardo-Pinto JP, Maghsoudlou P, Salazar GM, et al. Diagnosis of gynecologic malignancy after the treatment of presumed benign fibroid disease with interventional radiology procedures: a retrospective cohort study. Fertil Steril. 2023 Jul;120(1):125-133.